BioCryst Pharmaceuticals, Inc. (BCRX) 2023 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, and welcome to the BioCryst Pharmaceuticals' Third Quarter 2023 Earnings Conference Call. (Operator Instructions). Please note, this event is being recorded.

    各位早安,歡迎參加 BioCryst Pharmaceuticals 2023 年第三季財報電話會議。(接線員指示)請注意,本活動將被錄音。

  • I would like now to turn the conference over to John Bluth at BioCryst. Please go ahead.

    現在我想把會議交給 BioCryst 的 John Bluth。請開始。

  • John D. Bluth - Chief Communications Officer

    John D. Bluth - Chief Communications Officer

  • Thank you, Maria. Good morning, and welcome to BioCryst's Third Quarter 2023 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer and Chief Data and Insights Officer, Jinky Rosselli. Following our remarks, we'll answer your questions.

    謝謝你,Maria。各位早安,歡迎參加 BioCryst 2023 年第三季公司營運更新與財務結果電話會議。今天的新聞稿與隨附投影片已發布於我們的網站。今天與我一同出席的有執行長 Jon Stonehouse;財務長 Anthony Doyle;商務長 Charlie Gayer,以及數據與洞察長 Jinky Rosselli。在我們發言之後,將回答各位的提問。

  • As a reminder, tomorrow at 1:00 p.m. Eastern Time, we'll be hosting an R&D Day where we plan to describe our drug discovery process and introduce additional therapies from our pipeline. So today, we'll focus on ORLADEYO, and tomorrow, we'll take a deep dive and answer your question on our pipeline programs.

    提醒各位,明天美東時間下午 1:00,我們將舉辦研發日(R&D Day),屆時我們計畫說明我們的藥物發現流程,並介紹更多來自我們研發管線的療法。因此今天我們將聚焦 ORLADEYO;明天我們會深入探討並回答各位對我們管線專案的問題。

  • Before we begin, please note that today's conference call will contain certain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements.

    在開始之前,請注意今天的電話會議將包含若干前瞻性陳述,包括關於未來結果、未經審計且具前瞻性的財務資訊,以及公司未來表現和/或成就的陳述。這些陳述受到已知與未知風險及不確定性的影響,可能導致我們的實際結果、表現或成就與本簡報中明示或暗示的任何未來結果或表現存在重大差異。您不應過度依賴這些前瞻性陳述。

  • For additional information including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. In addition, today's conference call includes non-GAAP pro forma financial measures. For a reconciliation of these non-GAAP measures against the most directly comparable financial measures, please refer to the earnings press release posted in the press release section of our Investor Relations website at biocryst.com.

    如需更多資訊(包括對我們風險因素的詳細討論),請參閱公司向美國證券交易委員會(Securities and Exchange Commission)提交的文件,可於我們網站查閱。此外,今天的電話會議包含非 GAAP 的備考(pro forma)財務衡量指標。關於這些非 GAAP 指標與最直接可比的財務衡量指標之間的調節,請參閱發布於 biocryst.com 投資人關係網站新聞稿專區的財報新聞稿。

  • Now I'd like to turn the call over to Jon Stonehouse.

    現在我想把電話會議交給 Jon Stonehouse。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Thanks, John. Third quarter ORLADEYO revenue of $85.7 million was another strong quarter of performance and gives us a high degree of confidence we will achieve our goal of no less than $320 million for the year and remain on track for the $1 billion at peak. This growing revenue, along with discipline around our capital allocation, put us in a very strong financial position heading into the end of the year.

    謝謝,John。第三季 ORLADEYO 營收為 8,570 萬美元,再次展現強勁表現,讓我們對達成全年不低於 3.2 億美元的目標充滿信心,並持續朝向高峰期(peak)10 億美元的目標前進。這項持續成長的營收,加上我們在資本配置上的紀律,使我們在年底前處於非常強健的財務狀況。

  • Since we have more time today to discuss ORLADEYO, will go deeper into what we see in the market and how we see the market changing over time. As John mentioned, you will also hear from another member of the team today. Jinky has been with BioCryst for over 8 years. Jinky's title is Chief Data and Insights Officer, but to simply explain her role, Jinky gathers data and insights across the company and in the marketplace to help us understand the truth of what's really going on, not to look for data supporting what we hope to be true.

    由於今天有更多時間討論 ORLADEYO,我們將更深入說明我們在市場上看到的情況,以及我們如何看待市場隨時間的變化。如 John 所提,今天你們也會聽到團隊另一位成員的分享。Jinky 在 BioCryst 已任職超過 8 年。Jinky 的職稱是數據與洞察長(Chief Data and Insights Officer),但簡單來說,她的工作是彙整公司內部與市場上的數據與洞察,幫助我們理解真正正在發生的事實,而不是去尋找支持我們希望為真的數據。

  • This is a very important distinction. She will share the data and insights. She and her team have gathered around the HAE market and ORLADEYO, both today and what we see that will impact the future. We hope this will help you understand what we see and why we remain confident in our current growth trajectory and the path to peak revenue of $1 billion.

    這是一個非常重要的區別。她將分享她與團隊所蒐集、關於 HAE 市場與 ORLADEYO 的數據與洞察,包括現況以及我們認為將影響未來的因素。我們希望這能幫助各位理解我們所看到的情況,以及為何我們對目前的成長軌跡與通往 10 億美元高峰營收的道路仍然充滿信心。

  • Now I'll turn it over to Charlie to talk about the quarter's performance.

    現在我把時間交給 Charlie,請他談談本季表現。

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • Thanks, Jon. Patient growth in the third quarter continued at the consistent pace we have described before. The net growth in U.S. patients benefiting from ORLADEYO in Q3 was nearly identical to what we saw in each of the first 2 quarters this year, and our global growth continued to gain strength. As Jon noted upfront, we are excited to describe our expanding pipeline and its future promise tomorrow. Today, we are excited to describe the future we see for ORLADEYO. With Q3 revenues of $85.7 million and the consistent patient dynamics we are seeing, we repeat our guidance of no less than $320 million this year and are as confident as ever that ORLADEYO is on a path to $1 billion in peak global revenue.

    謝謝,Jon。第三季病患成長持續以我們先前描述的一致步調推進。第三季美國使用 ORLADEYO 受益的病患淨成長,幾乎與今年前兩季所見相同,而我們的全球成長也持續增強。如 Jon 一開始所提,我們很期待在明天說明我們擴展中的研發管線及其未來潛力。今天,我們很高興描述我們所看到的 ORLADEYO 未來。第三季營收 8,570 萬美元,加上我們所看到一致的病患動態,我們重申今年不低於 3.2 億美元的指引,並且比以往任何時候都更有信心,ORLADEYO 正走在全球高峰營收 10 億美元的道路上。

  • I'm going to describe the pattern of growth that we have seen and show you how we believe this pattern will translate to that peak. Jinky will describe in more depth how we validate these forecasts. As a side note, I first worked with Jinky at another company starting in 2007. She is the main reason I joined BioCryst right behind her in 2015. I joined not only because I enjoy working with her and her team, but because they do objective, insightful, patient-focused work that I believe tells the truth about the future for ORLADEYO as closely as could ever be predicted.

    我將說明我們所看到的成長模式,並向各位展示我們認為這種模式將如何轉化為高峰期表現。Jinky 會更深入說明我們如何驗證這些預測。順帶一提,我在 2007 年於另一家公司首次與 Jinky 共事。她是我在 2015 年緊跟著她加入 BioCryst 的主要原因。我加入不僅因為我喜歡與她及其團隊合作,也因為他們做的是客觀、有洞察力、以病患為中心的工作;我相信這些工作能盡可能貼近可預測的程度,揭示 ORLADEYO 的未來真相。

  • Let's look at the data. We included 2 slides in our earnings deck that described ORLADEYO growth. The first, Slide 4 shows the monthly pattern of U.S. patient prescriptions and patient discontinuations graphed on the same Y axis. You can see that months bump up and down over the last 8 quarters, but the range is tight. New starts to date have been well above discontinuations, we had good months, great months, just okay months, leading to trend lines of start forms and discontinuations over the past 2 years that are essentially flat.

    我們來看數據。我們在財報簡報中放了 2 張投影片來描述 ORLADEYO 的成長。第一張是第 4 頁,顯示美國病患處方的每月模式,以及病患停用(discontinuations),並以相同的 Y 軸繪圖。你可以看到過去 8 個季度中,各月份有上下波動,但區間很窄。迄今新開始用藥(new starts)明顯高於停用;我們有不錯的月份、很棒的月份、也有普通的月份,導致過去 2 年開始用藥表單與停用的趨勢線基本上是平坦的。

  • That means the growth of net patients on therapy remains very linear. Net Patients on the secondary Y axis. We have not shown the numbers on the chart, but we crossed 1,000 U.S. patients on ORLADEYO in early May and are well above that point now. This U.S. patient growth, combined with reimbursement dynamics, shipping days and other factors create variable revenue patterns, you can see on the right slide of Slide 4. Q1 tends to be down because of reauthorization. Q2 jumps up after reauthorization is complete and Q3 and Q4 tend to go up more gradually.

    這表示治療中的病患淨成長仍然非常線性。淨治療病患數(Net Patients)在次要 Y 軸上。我們沒有在圖表上顯示數字,但我們在 5 月初跨越了 1,000 名美國 ORLADEYO 病患的門檻,現在已遠高於該水準。這樣的美國病患成長,結合給付(reimbursement)動態、出貨天數及其他因素,會造成營收模式的變動,你可以在第 4 頁右側圖表看到。第一季通常因為重新授權(reauthorization)而較低;第二季在重新授權完成後跳升;第三季與第四季則通常較為逐步上升。

  • However, the long-term revenue trend follows the patient growth trends. So where is ORLADEYO heading? Slide 5 shows you what we expect based on what we see today. I'll walk you through some simple numbers that are representative of our data and our view. I've simplified and approximated the numbers, but precision is not important because the long-term view does not change. We expect to end 2023 with roughly 1,050 patients who have reached a state of either paid therapy or long-term free product or PAP.

    然而,長期營收趨勢會跟隨病患成長趨勢。那麼 ORLADEYO 將走向何處?第 5 頁展示了我們根據目前所見的預期。我會用一些簡單數字帶各位走過,這些數字代表我們的數據與觀點。我已將數字簡化並做近似處理,但精確度並不重要,因為長期觀點不會改變。我們預期在 2023 年底約有 1,050 名病患達到以下狀態之一:已付費治療(paid therapy)、長期免費用藥,或 PAP。

  • We also have a population of newly prescribed patients on short-term quick start free product at any given time. And when you include them, the proportion of patients on paid product is just under 70%. I'm going to exclude the quick start patients because the coverage for them is still pending. That leaves us with a paid patient ratio of about 73%, which is what I will use for this analysis. The 1,050 year-end patient base multiplied through a compliance rate of just over 90% and a gross to net reduction of 15% to 20% off WAC list price on paid patients gets to an annualized rate of about $310 million per year. Our patient growth history plus forecasting methods that Jinky will describe, give us confidence we will average around 200 net patient additions per year through 2028.

    此外,在任何時間點,我們也有一群新近開立處方、正在使用短期 quick start 免費用藥的病患。若將他們納入,使用付費產品的病患占比略低於 70%。我將排除 quick start 病患,因為他們的保險給付仍在等待核定。如此一來,付費病患比率約為 73%,我將在本分析中使用此數字。以年底 1,050 名病患基礎,乘上略高於 90% 的依從性(compliance)比率,以及在付費病患上相對於 WAC 標價的 15% 至 20% 毛額到淨額(gross to net)減項,可得出年化約 3.10 億美元的水準。我們的病患成長歷史,加上 Jinky 將說明的預測方法,使我們有信心在 2028 年之前每年平均可增加約 200 名淨新增病患。

  • We have averaged a bit above that rate for the past 2 years, and I've shown you the consistency. Growth could be more some years, less others, but we expect to add 1,000 net patients by the end of 2028, which adds up to an additional $295 million in annualized revenue. By the end of 2028, we are looking at a minimum of just over $600 million annualized U.S. revenue without any other changes. But we also expect the 73% paid ratio to grow to 85% based on the work we are doing and the trends we are seeing. Most of that percentage improvement plus the revenue growth impact will not happen in 2024. The percentage growth will accrue over the next 3 to 4 years. With over 2,000 patients, that improvement would be worth at least $100 million per year by 2029, making steady-state U.S. revenue around $700 million per year.

    過去 2 年我們的平均增速略高於這個水準,而我也向各位展示了其一致性。某些年度成長可能較多、某些年度較少,但我們預期到 2028 年底可新增 1,000 名淨病患,合計可帶來額外約 2.95 億美元的年化營收。到 2028 年底,在沒有其他變化的情況下,我們預期美國年化營收至少略高於 6 億美元。但我們也預期付費比率 73% 將在我們正在進行的工作與所見趨勢的推動下提升至 85%。其中大部分的比例改善及其對營收成長的影響不會在 2024 年發生;比例提升將在接下來 3 到 4 年逐步累積。當病患數超過 2,000 名時,這項改善到 2029 年每年至少可增加 1 億美元,使美國穩態(steady-state)營收約為每年 7 億美元。

  • Now assume a very modest average annual price increase through early 2029. And you can see how U.S. revenues are likely to reach $800 million or more in 2029. The early trends we see outside the U.S. give us confidence that ORLADEYO will reach around $200 million in the rest of the world, completing the path to $1 billion in global revenue around the turn of the decade. The results that we have seen and the path we are on are not surprising to us. ORLADEYO is a highly differentiated product that HAE patients wanted back in 2020, and they continue to want today. Jinky will tell you more about how we use robust insights on patients and health care providers to predict where ORLADEYO is heading. Jinky, welcome to today's earnings call.

    現在假設到 2029 年初為止,每年的平均價格僅有非常溫和的上漲。你可以看到,美國營收很可能在 2029 年達到 8 億美元或以上。我們在美國以外看到的早期趨勢,讓我們有信心 ORLADEYO 在全球其他地區可達約 2 億美元,從而在十年交替之際完成全球營收達 10 億美元的路徑。我們所看到的結果以及我們正走的路,對我們而言並不意外。ORLADEYO 是一款高度差異化的產品,HAE 病患在 2020 年就想要,至今仍然想要。Jinky 會進一步說明我們如何運用對病患與醫療照護提供者的強健洞察,來預測 ORLADEYO 的走向。Jinky,歡迎加入今天的財報電話會議。

  • Jinky Ang Rosselli - Chief Data & Insights Officer

    Jinky Ang Rosselli - Chief Data & Insights Officer

  • Thanks, Charlie. We truly believe that robust and thoughtful methods are critical in providing and understanding of not only the drivers of demand for ORLADEYO, but a complete unbiased reflection of the overall HAE market. Charlie mentioned in past calls, our quarterly market research studies showing consistent strong demand for ORLADEYO. These quarterly studies serve a robust and generalizable example of HAE prescribers and HAE patients.

    謝謝你,Charlie。我們確實相信,強健且周延的方法對於提供並理解不僅是 ORLADEYO 需求的驅動因素、也包括對整體 HAE 市場的完整且不偏不倚的反映,至關重要。Charlie 在過去的電話會議中提到,我們的季度市場研究顯示 ORLADEYO 的需求持續強勁。這些季度研究為 HAE 開立處方醫師與 HAE 病患提供了一個強健且可推廣的樣本例證。

  • A key question we asked consistently in these studies is potential prescribing over the next 12 months. We feel this question is a good metric to keep us informed of on-demand and shifts in that demand. Latest studies show that HAE physicians anticipate prescribing ORLADEYO to about 25% of their patients in the next 12 months. These data on future prescribing of ORLADEYO have been consistent study over study, reinforcing our assumptions, the demand remains strong.

    我們在這些研究中持續提出的一個關鍵問題,是未來 12 個月的潛在開立處方情況。我們認為這個問題是一個良好的指標,可讓我們掌握即時需求以及需求的變化。最新研究顯示,HAE 醫師預期在未來 12 個月內,會將 ORLADEYO 開立給其約 25% 的病患。這些關於 ORLADEYO 未來處方的數據在一項又一項研究中保持一致,強化了我們的假設:需求仍然強勁。

  • We do recognize that the HAE market is competitive and is likely to get more competitive. Our market research shows that products with a strong value proposition are sticky, meaning prescribers and patients are loyal. Across our volumes of research over the years, HAE patients have consistently expressed how grateful they are for every new therapy available to them which is totally understandable given HAE is a rare disease with historically limited options. These patients have also indicated a high level of satisfaction with their treatments. When our quantitative data prelaunch showed this level of satisfaction, I admit, I did have a moment of panic.

    我們確實認知到 HAE 市場競爭激烈,且很可能會變得更具競爭性。我們的市場研究顯示,具備強價值主張的產品具有黏著性,也就是說,開立處方者與病患會保持忠誠。多年來大量研究一致顯示,HAE 病患持續表達他們對每一種可用新療法的感激之情——這完全可以理解,因為 HAE 是罕見疾病,過去可選擇的治療方式有限。這些病患也表示對其治療具有高度滿意度。當我們在上市前的量化數據顯示出這樣的滿意度時,我承認我確實有過一瞬間的恐慌。

  • In past market type studies when customers are highly satisfied, the implication is that there are no remaining unmet needs. But digging further into the research in these highly satisfied HAE patients, we're offering the promise of an oral therapy. Over 50% were willing to switch from their existing prophylactic therapy to ORLADEYO. Patients' willingness to switch to ORLADEYO signal that there are still unmet needs, namely controlling their attacks as no treatment is perfect and treatment burdens associated with their current injectables. The core insight here is that these patients are expert covers and will, therefore, always indicate high levels of satisfaction. Simply stated these HAE patients are seeking a freedom and an improved quality of life.

    在過去的市場類型研究中,當客戶高度滿意時,通常意味著已沒有未被滿足的需求。但當我們進一步深入研究這些高度滿意的 HAE 病患時,我們提供的是口服治療的承諾。超過 50% 的人願意從其既有的預防性治療轉換到 ORLADEYO。病患願意轉換到 ORLADEYO,顯示仍存在未被滿足的需求,主要包括:控制發作(因為沒有任何治療是完美的),以及與其目前注射劑相關的治療負擔。這裡的核心洞察是,這些病患是「專家應對者」,因此總是會表示高度滿意。簡而言之,這些 HAE 病患追求的是更大的自由與更佳的生活品質。

  • As we continue to mine our actual ORLADEYO data and study our sources of business, we do see this intent stated in research proving out in our population. Top 3 reasons our actual patients have stated as reasons to switch to ORLADEYO include wanting to reduce number of attacks, wanting to reduce severity of attacks and wanting to reduce the burden of current treatment. Their motivation for switching is wanting more. The reason for staying on therapy based on research with current patients is essentially the same. Less frequent and severe attacks in addition to the convenience of an oral, which reduces the treatment burden. Assumptions for our forecast rely heavily on insights from market studies, our conduit work and ultimately, a simulation model. Collectively, these approaches helped us quantify demand, an uptake not only to ORLADEYO, but also impact of the competition.

    隨著我們持續挖掘實際 ORLADEYO 數據並研究我們的業務來源,我們確實看到研究中表達的意向在我們的族群中得到驗證。我們的實際病患所陳述、轉換到 ORLADEYO 的前三大原因包括:希望減少發作次數、希望降低發作嚴重程度,以及希望減輕目前治療的負擔。他們轉換的動機是想要更多。基於對現有病患的研究,持續用藥的原因本質上也相同:更少且更不嚴重的發作,加上口服用藥的便利性,從而降低治療負擔。我們的預測假設高度依賴市場研究、我們的導管(conduit)工作,以及最終的模擬模型。綜合而言,這些方法幫助我們量化需求、ORLADEYO 的採用速度,以及競品的影響。

  • Unlike traditional mass market, rare disease markets really have prescription data to build forecasts upon. Hence, we supplement and collect as much data as possible through primary methods to fill these gaps. In our most recently completed conjoint study, our sample included 175 HAE treaters and 100 HAE patients. We ask stakeholders to allocate brand preference in terms of current use and the potential future use including the competition in their choice sets. We then analyze these preference data and incorporate them into market models driven by Monte Carlo simulation. Our simulation models can provide the most probable estimates of patient numbers, market shares and ramp to peak for ORLADEYO.

    不同於傳統的大眾市場,罕見疾病市場其實缺乏可用來建立預測的處方數據。因此,我們透過第一手方法補充並盡可能蒐集更多數據,以填補這些缺口。在我們最近完成的聯合分析(conjoint)研究中,樣本包含 175 位 HAE 治療醫師與 100 位 HAE 病患。我們請利害關係人就其選擇集合中的品牌(包含競品),在目前使用與未來可能使用方面分配品牌偏好。接著我們分析這些偏好數據,並將其納入以蒙地卡羅模擬驅動的市場模型。我們的模擬模型可提供 ORLADEYO 病患人數、市占率以及達到峰值的爬坡路徑之最可能估計。

  • Monte Carlo simulations allow us to run hundreds of iterations in the simulator and the models continue to reinforce confidence in reaching 2,000 patients at peak in the U.S. even with competition entering the market. In the near term, the model confirmed by actual has shown strong ORLADEYO uptake with its source of business from prophy naive and prophy switches. In the outer years to peak, assuming a conservative scenario that all investigational products reach the market, our research consistently shows that new injectable products will take share mainly from current injectables by claiming the convenience of less frequent injections. Despite that, our model see TAKHZYRO remaining as the leading injectable products because less frequent injections are an incremental benefit that will not be sufficient to drive many patients to switch.

    蒙地卡羅模擬讓我們能在模擬器中執行數百次迭代,而模型持續強化我們的信心:即使有競品進入市場,美國在峰值時仍可達到 2,000 名病患。就近期而言,模型並由實際數據驗證,顯示 ORLADEYO 的採用強勁,其業務來源來自於預防治療新手(prophy naive)以及預防治療轉換者(prophy switches)。在通往峰值的較長期年度中,若採取保守情境、假設所有研發中產品都能上市,我們的研究一致顯示:新的注射型產品將主要從現有注射劑手中取得市占,主打更低頻率注射的便利性。儘管如此,我們的模型仍認為 TAKHZYRO 將維持為領先的注射型產品,因為注射頻率降低屬於增量式利益,並不足以驅動大量病患轉換。

  • Switching from an injectable to oral, however, offers a much more dramatic benefit to many patients. Our model anticipates that ORLADEYO will most likely be insulated from these new injectable entrants. Likewise, our research and model anticipates minimal switching away from ORLADEYO to any new oral because any new product is unlikely to offer a meaningful benefit over what they already experience with ORLADEYO. Similar to how TAKHZYRO remains sticky -- as a sticky market-leading injectable in the outer years, our research and data show that ORLADEYO will be equally sticky as a market-leading oral. We strongly believe in continuous optimization of our forecasting methods. Post launch, our models will evolve with additional levels of sophistication, including actual ORLADEYO data like patient adds, discontinuations, overall patients on therapy and other market dynamics that could affect near-term revenue performance.

    然而,從注射轉為口服,對許多病患而言帶來更顯著的效益。我們的模型預期 ORLADEYO 很可能能夠免受這些新注射型競品進入的影響。同樣地,我們的研究與模型也預期,從 ORLADEYO 轉換到任何新的口服藥的情況將非常有限,因為任何新產品不太可能在病患已從 ORLADEYO 所獲得的體驗之上提供有意義的額外效益。就像 TAKHZYRO 在較長期年度仍具黏著性——作為市場領先且具黏著性的注射型產品——我們的研究與數據顯示,ORLADEYO 作為市場領先的口服藥也將同樣具黏著性。我們堅信持續優化預測方法。上市後,我們的模型將隨著更高層次的精細化而演進,納入更多實際 ORLADEYO 數據,例如新增病患、停藥、治療中的總病患數,以及其他可能影響短期營收表現的市場動態。

  • We have found historically that our models correlate strongly with actuals and have predicted ORLADEYO patient numbers and corresponding revenues reliably. Forecasting year 1 of launch is always difficult. But a year prior to launch of ORLADEYO, our model showed U.S. revenues approaching $100 million, and our actual year 1 revenues came in at $122 million.

    從歷史經驗來看,我們的模型與實際結果高度相關,並且能可靠地預測 ORLADEYO 的病患人數及相應營收。上市第一年的預測一向困難。但在 ORLADEYO 上市前一年,我們的模型顯示美國營收接近 1 億美元,而我們實際的第一年營收為 1.22 億美元。

  • Beyond forecasting, our team also study these data in depth to help better understand the needs of our patients, our physicians and points to opportunities for optimization of our patient services in real time. With availability data on a granular level, coupled with robust market insights, our team can proactively partner with the commercial teams with a full story of ORLADEYO. Our commercial teams are always ready to action on the truth from these data, ready with strategies and solutions to address any of the findings. Quantitative evidence direct from our customers from the basis of all our assumptions. Full market context, including the competition are always incorporated into our thinking, having a strong commercial team ready to action on the data and intake also key. Because we anchor in all these variables collectively, we have a strong level of confidence in our views of future ORLADEYO performance and our path to $1 billion.

    除了預測之外,我們的團隊也會深入研究這些數據,以更好地理解病患需求、醫師需求,並即時找出可優化病患服務的機會。透過細緻層級的可得性數據,結合強健的市場洞察,我們的團隊能以前瞻方式與商業團隊合作,提供 ORLADEYO 的完整敘事。我們的商業團隊總是準備好依據這些數據所揭示的事實採取行動,並備有策略與解決方案以回應任何發現。直接來自客戶的量化證據構成我們所有假設的基礎。我們的思考一向納入完整的市場脈絡(包括競品),同時也需要一支強大的商業團隊,能夠對數據與回饋迅速採取行動。由於我們共同錨定於所有這些變數,我們對 ORLADEYO 未來表現的觀點以及通往 10 億美元的路徑,具有高度信心。

  • Anthony, I'll turn it over to you.

    Anthony,接下來交給你。

  • Anthony J. Doyle - Senior VP & CFO

    Anthony J. Doyle - Senior VP & CFO

  • Thanks, Jinky. With Q3 ORLADEYO revenue coming in at $85.7 million, we are well positioned to achieve our 2023 guidance of no less than $320 million. Longer term, Charlie and Jinky outlined the growth factors that we expect in the coming years, giving us great confidence in getting to $1 billion in peak revenue. You can find our detailed third quarter financials in today's earnings press release, and I'd like to call your attention to a few items.

    謝謝你,Jinky。第三季 ORLADEYO 營收為 8,570 萬美元,我們已具備良好條件達成 2023 年指引:不低於 3.2 億美元。就長期而言,Charlie 與 Jinky 概述了我們預期未來幾年的成長因素,讓我們對達到 10 億美元的峰值營收充滿信心。你可以在今天的財報新聞稿中找到我們第三季的詳細財務資訊,我想特別請各位注意幾個項目。

  • Total revenue for the quarter was $86.7 million, $85.7 million of which came from ORLADEYO, putting ORLADEYO trailing 12-month revenue at approximately $306 million. Of the $85.7 million of global ORLADEYO revenue $75.3 million came from U.S. sales with the remaining $10.4 million coming from ex-U.S. Operating expenses, not including noncash stock compensation for the quarter were approximately $85.9 million. We are revising our full year guidance for OpEx to $365 million to $375 million based on current trending and as we continue to be disciplined in our approach to capital allocation.

    本季總營收為 8,670 萬美元,其中 8,570 萬美元來自 ORLADEYO,使 ORLADEYO 過去 12 個月的營收約為 3.06 億美元。在 ORLADEYO 全球營收 8,570 萬美元中,7,530 萬美元來自美國銷售,其餘 1,040 萬美元來自美國以外地區。本季營業費用(不含非現金股票薪酬)約為 8,590 萬美元。基於目前趨勢,並在我們持續以嚴謹方式進行資本配置之下,我們將全年 OpEx 指引修訂為 3.65 億至 3.75 億美元。

  • Cash at the end of the third quarter was $399.2 million, and net cash utilization for the quarter was approximately $16 million. One of the areas that investors and analysts have been asking for additional information related to debt and royalties. So let me go into a little bit more detail on them.

    第三季末的現金為3.992億美元,本季淨現金使用約為1,600萬美元。投資人與分析師一直要求我們提供更多與債務與權利金相關的資訊,因此我將就此再多做一些說明。

  • Looking high level at our balance sheet, total long-term debt is listed at approximately $833 million. However, only around $300 million of that is traditional debt and the remainder relates to future royalty obligations. Earlier this year, we refinanced our term loan with Pharmakon. This $300 million is traditional debt with traditional characteristics, a 5-year term interest-only payments during the loan period, like financial covenants and Apollo payment due in 2028. Separately, between 2020 and 2021, we secured an aggregate of $425 million for Royalty financing from Royalty Pharma and from owners. For this instrument, we forecast future revenue and based on that future royalty is payable, which we then use to calculate an effective interest rate.

    從資產負債表的高層次來看,長期負債總額約列為8.33億美元。然而,其中只有約3億美元屬於傳統債務,其餘則與未來的權利金義務相關。今年稍早,我們與Pharmakon為我們的定期貸款進行再融資。這3億美元是具備傳統特性的傳統債務:5年期、貸款期間僅付利息,並包含財務契約條款,以及於2028年到期需支付Apollo款項。另方面,在2020年至2021年間,我們自Royalty Pharma及其他持有人取得合計4.25億美元的權利金融資。對於此工具,我們會預測未來營收,並依據該預測計算應支付的未來權利金,進而用以計算有效利率。

  • On a quarterly basis, we accrue interest expenses related to this effective interest rate on the P&L, while between periods, the balance sheet movement is the delta between the interest expense accrued and the actual royalties paid. The amount currently on the balance for this is $533 million, meaning we have accrued more interest expense than we've actually paid in royalties. At the future point, these balances should decrease as revenues increase and as royalties payable should, at that point, be higher than interest expense.

    按季度,我們會在損益表(P&L)上依該有效利率計提相關利息費用;而在各期間之間,資產負債表的變動則為已計提的利息費用與實際已支付權利金之差額。目前此項在資產負債表上的餘額為5.33億美元,代表我們計提的利息費用高於實際支付的權利金。未來隨著營收增加,且屆時應付權利金應高於利息費用,這些餘額理應會下降。

  • GAAP reporting, this is considered to be a debt instrument. However, this is not traditional debt. These payments are based entirely on securing ORLADEYO revenue, i.e., no revenue, no royalties. Additionally, there's no recourse. The balances are not callable, and there is no bullet payment. Hopefully, this additional detail helps. We look forward to sharing more exciting information on our pipeline with you at the R&D Day tomorrow, and I hope you can join us then.

    在GAAP報導下,這被視為一項債務工具。然而,這並非傳統債務。這些付款完全取決於ORLADEYO營收的取得,也就是說,沒有營收就沒有權利金。此外,沒有追索權。這些餘額不可被提前贖回,也沒有一次性到期本息(bullet payment)。希望這些補充細節能有所幫助。我們期待在明天的研發日(R&D Day)與各位分享更多令人振奮的產品線資訊,也希望各位能一同參與。

  • Operator, we would now like to open the call up for Q&A.

    接線員,我們現在想開放電話會議進入問答(Q&A)環節。

  • Operator

    Operator

  • (Operator Instructions) The first question is from Tazeen Ahmad of Bank of America.

    (接線員指示)第一個問題來自美國銀行(Bank of America)的Tazeen Ahmad。

  • Tazeen Ahmad - MD in Equity Research & Research Analyst

    Tazeen Ahmad - MD in Equity Research & Research Analyst

  • I have a couple. Thanks so much for providing that really detailed analysis of how you see the market evolving. I think in some of my discussions with investors, I often get asked about the benefits of ORLADEYO versus the ramp rate for the launch itself. So while you're feeling a high sense of confidence that by the end of the decade, you'll be looking at $1 billion, what do you think would need to happen to speed up that launch in order for the steepness of uptake to increase relative to where you are now? And then I have a follow-up.

    我有幾個問題。非常感謝你們提供如此詳盡的分析,說明你們如何看待市場演變。我想在我與投資人的一些討論中,常被問到ORLADEYO的優勢,相較於產品上市初期的爬坡速度。因此,雖然你們對於在本十年末達到10億美元充滿信心,但你們認為要加速這次上市、讓採用曲線的上升斜率相較於目前更陡,需要發生哪些事情?另外我還有一個追問。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Charlie, you want to take that?

    Charlie,你要回答嗎?

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • Sure. So first of all, we're really happy with the ramp rate and the consistent ramp rate and where it's headed. So we're always looking for ways to make it go a little bit faster. And we've talked about patient activation before. That's definitely one. We don't see any one thing that can be done that's going to meaningfully bend it up. But we just -- we plan to keep executing really consistently. And we're going to get there. I think when you look at the ramp rate of 200 patients adds per year that is very realistic and very achievable over the next 5 years. So we're happy to keep it just at the ramp it's at.

    當然。首先,我們對目前的爬坡速度、其一致性以及未來走向都非常滿意。我們也一直在尋找讓它再快一些的方法。我們之前談過病患啟動(patient activation),那確實是一個方向。我們不認為有任何單一措施能夠顯著把曲線往上拉升。但我們會——我們計畫持續非常一致地執行。我們會達成目標的。我認為,若看每年新增200位病患的爬坡速度,在未來5年是非常現實且非常可達成的。因此我們樂於維持目前這樣的爬坡節奏。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Yes. One the other thing I'd add to Tazeen and Jinky stressed this a lot in her remarks, is remember that there's a lot of competition and patients are very satisfied with their therapy. When we talk to patients, they'll tell us, "Oh, my god, this saved my life, this changed my life" and they're on the injectable therapy. So that stickiness is just takes time to break and get people to understand that they could do better with an oral. But then on the flip side, that's going to work to our advantage when other competitors come out. So I think the ramp rate is considering the competition in a rare disease is phenomenal.

    是的。我還想補充一點給Tazeen,而Jinky在她的發言中也強調很多:請記得市場競爭很激烈,而且病患對他們目前的治療非常滿意。我們與病患交談時,他們會告訴我們:「天啊,這救了我的命,這改變了我的人生」,而他們使用的是注射療法。因此,這種黏著度需要時間才能被打破,並讓大家理解口服治療可能會更好。但反過來說,當其他競爭者推出時,這也會成為我們的優勢。所以我認為,在罕見疾病且競爭存在的情況下,這樣的爬坡速度是非常出色的。

  • Tazeen Ahmad - MD in Equity Research & Research Analyst

    Tazeen Ahmad - MD in Equity Research & Research Analyst

  • Okay. And then as a follow-up, when you talk about the 2,000 patients as your target, what type of a discontinuation rate is assumed in that? Are those 2,000 patients taking the drug continually or 2,000 patients that will touch the target?

    好的。接著追問,當你們談到以2,000位病患作為目標時,這裡假設的停藥率(discontinuation rate)是多少?這2,000位病患是持續用藥的2,000位,還是指曾經使用過、觸及目標的2,000位?

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • And Charlie talk about the pattern as well.

    Charlie,也請談談使用型態。

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • Yes. Yes. No, absolutely. So Tazeen first of all, the pattern that we've described before has been it's still the same. And the slide I showed today I think demonstrates that. So when a patient starts on ORLADEYO, 60% of those patients make it through the first year. And then we see very little discontinuation after that. There's always a little bit, but those are the sticky patients really once they make it to a year. And so once we get to the 2,000, we see a base of about 2,000 patients being sticky and staying on ORLADEYO. And then as we've talked about before, we have patent protection out to 2039. So it's a long ramp potentially at peak sales of $1 billion with those 2,000 patients. And that's just the U.S., the same dynamics will apply in other markets.

    是的,當然。Tazeen,首先,我們之前描述的使用型態仍然相同。我想我今天展示的投影片也說明了這點。當病患開始使用ORLADEYO時,其中60%會持續到第一年結束。之後我們看到的停藥就非常少了。總是會有一點,但一旦撐過一年,這些病患就真的很黏著。因此當我們達到2,000位時,我們看到的是約2,000位病患作為穩定基礎,會黏著並持續使用ORLADEYO。再如我們之前提到的,我們的專利保護可延伸至2039年。因此,若以這2,000位病患達到10億美元的峰值銷售,可能會是一段很長的爬坡期。而這只是美國;其他市場也會有相同的動態。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Yes. So you should think that the -- when we get to the 2,000, we mean they've been on for at least a year or much longer and you're going to lose a percentage or 2 each year, but you're going to get that back in.

    是的。所以你應該這樣理解——當我們說達到2,000位時,是指他們至少已用藥一年或更久。你每年可能會流失1%到2%,但你也會把那部分補回來。

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • We're going to replace it.

    我們會補上。

  • Operator

    Operator

  • The next question is from Stacy Ku of TD Cowen.

    下一個問題來自TD Cowen的Stacy Ku。

  • Stacy Ku - VP

    Stacy Ku - VP

  • Congratulations on the progress, and we really appreciate the detailed analysis of ORLADEYO. So first, we have a question. Could you further elaborate on your expectations for consistent linear growth Specifically, how are you thinking about 2024? What are your thoughts on $410 million roughly for consensus? That's the first question. And then one more on this year. So do you have any updated thoughts on your guidance of at least $320 million. If there is any potential for outperformance, what factors you expect could drive better sales? Is it ex U.S.? Any kind of detailed thoughts around this year would be appreciated.

    恭喜你們的進展,也非常感謝你們對ORLADEYO所做的詳細分析。首先我們有個問題:你們能否進一步說明對於「穩定線性成長」的預期?具體而言,你們如何看待2024年?對於市場共識大約4.10億美元,你們有何看法?這是第一個問題。接著還有一個關於今年的問題:你們對於至少3.20億美元的指引是否有任何更新想法?若有超預期的可能性,你們預期哪些因素可能推動更好的銷售?是美國以外(ex U.S.)嗎?若能提供今年更細的看法將不勝感激。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Yes, we don't comment on consensus and we haven't guided yet for next year, but I do think Charlie made some comments in his prepared remarks, that should set expectations so I'll let him talk.

    是的,我們不評論市場共識,而且我們也尚未對明年提供指引。不過我確實認為Charlie在事先準備的發言中做了一些評論,應能建立預期,所以我讓他來說明。

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • Yes. I think for next year and for the next 5 years, we expect average about 200 patient adds and that could be a little more, some years a little less, it won't be exactly that every year, but with consistent growth, it's going to be pretty close. And on the $320 million we're very confident in the 320. We've been saying for multiple quarters now put 320 in your model, and I think we'd say do the same right now.

    是的。我認為明年以及未來5年,我們預期平均每年約新增200位病患;某些年份可能多一些、某些年份少一些,不會每年都剛好一樣,但在穩定成長下會非常接近。至於3.20億美元,我們對3.20億非常有信心。我們已經連續好幾季都在說把3.20億放進你的模型裡,我想我們現在也會說同樣的話。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • I think the challenge with next year is the cap to paid that were not completely sure how the IRA is going to impact the Medicare patients. There's still infrastructure that Charlie is putting in place and executing on where he's making great progress on the front end of making sure Quick Start gets to paid on a higher frequency, but we still have those long-term path folks that we've got to get switched over to paid. So in the -- I think it was around $100 million, Charlie, that you said over the next 5 years will benefit from those switch...

    我認為明年的挑戰在於已付費(paid)的上限(cap to paid),我們還不完全確定《降低通膨法案》(IRA)將如何影響Medicare病患。仍有一些基礎建設是Charlie正在建立並執行的,他在前端確保Quick Start能以更高頻率轉為已付費方面進展很好,但我們仍有那些長期路徑(long-term path)的個案需要轉為已付費。所以在——我想大約是1億美元,Charlie,你說在未來5年會因那些轉換而受益……

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • Yes, $100 million would come in 2029 after we move the paid ratio to 85%.

    是的,在我們把已付費比率提升到85%之後,那1億美元會在2029年進來。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • So you shouldn't expect much progress on that, next year is the point I'm trying to make.

    所以我的意思是,你不應該預期明年在這方面會有太多進展。

  • Stacy Ku - VP

    Stacy Ku - VP

  • Okay. And then on ex U.S., what are you thinking there? You've given kind of some guidance around the breakdown, but it looks like there's some nice sales there. So any comments on that would be appreciated.

    好的。那美國以外(ex U.S.)方面你們怎麼看?你們對拆分已提供一些指引,但看起來那邊有不錯的銷售表現。所以若能評論一下將不勝感激。

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • Yes. I mean ex U.S. is going really well. We continue to get -- have market access wins. We continue to launch in new markets. We continue to grow in the first wave of markets where we're at. As we've commented before, the price is lower. So it's a volume game. It's longer term. That everything that we see ex U.S. tells us it will contribute that additional $200 million by about the turn of the decade.

    是的。我的意思是,美國以外的表現非常好。我們持續取得——獲得市場准入的勝利。我們持續在新市場上市。我們也持續在第一波已進入的市場成長。如同我們之前評論過的,價格較低,所以這是一個靠量的遊戲,屬於較長期的布局。我們在美國以外看到的一切都告訴我們,到本十年末前後,它將貢獻額外約2億美元。

  • Anthony J. Doyle - Senior VP & CFO

    Anthony J. Doyle - Senior VP & CFO

  • Like Charlie said about the link between patient growth and then revenue similar in ex U.S., there will be some puts and takes, right? There'll be some peaks and troughs for each quarters that are bigger quarters that are smaller, depending on which territories we're selling into. But overall, the trend continues to be really strong.

    就像 Charlie 談到病患成長與營收之間的連動、在美國以外市場也類似一樣,這中間會有一些此消彼長,對吧?每一季都會有一些高峰與低谷,有些季度會比較大、有些會比較小,取決於我們銷售到哪些區域。但整體而言,趨勢仍然非常強勁。

  • Operator

    Operator

  • Next question is from Maury Raycroft of Jefferies.

    下一個問題來自 Jefferies 的 Maury Raycroft。

  • Unidentified Analyst

    Unidentified Analyst

  • This is (inaudible) on for Maury. Congrats on a successful quarter. I guess our first question is on patients on free drug program, which went down from 34% in Q1 at peak to about 30% by the end of Q2. Can you maybe provide more color on what you saw in Q3? And where do you think that will be by year-end?

    我是(聽不清)代替 Maury 發問。恭喜本季表現亮眼。我想我們第一個問題是關於免費用藥計畫的病患比例,該比例在第一季高峰時從 34% 降到第二季末約 30%。你能否多分享一些第三季看到的情況?以及你認為到年底會落在什麼水準?

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Charlie?

    Charlie?

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • Yes. So good question. And we said we were at 30% at the end of Q2. I noted on the prepared remarks today that essentially, that number is a little over 30% in Q3. What we saw in Q3 is a couple of factors that affected that. And these kind of wobbles are going to happen as we make that long-term progress towards 85% paid. But in Q3, we saw some Medicaid patients moving temporarily, we think, to free product as some of the COVID release funding ended. We also saw -- it's re-enrollment season insurance companies. And so some patients actually moved as their switching plans moved temporarily to free product.

    好的,這是個好問題。我們說過第二季末是 30%。我今天在事先準備的發言中也提到,第三季這個數字基本上略高於 30%。第三季我們看到有幾個因素影響了這個比例。當我們朝長期目標、也就是 85% 付費用藥的方向前進時,這類波動是會發生的。但在第三季,我們看到一些 Medicaid 病患在 COVID 相關釋出資金結束後,我們認為是暫時性地轉到免費用藥。另外,我們也看到——現在是保險公司重新投保的季節,所以有些病患在更換方案的過程中也暫時轉到免費用藥。

  • And then the other piece that is driving up just a little bit, the percentage of free product is that as we're improving our processes to get people to pay, we're actually slowing down a bit to get better results. So when new patients come in, we're keeping them on the Quick Start program for a little bit longer to make sure that we've got a really comprehensive case for the insurers so that we actually improve the percentage of paid. And we're seeing that paying off. So amongst our commercial segment, which is about 60% of our patients, we now see that over 80% of them are on paid therapy. And so that's one of those trends that gives us confidence in the long term that we're going to get to 85%.

    另外一個讓免費用藥比例略微上升的因素是:當我們改善流程、讓更多人轉為付費用藥時,我們其實會稍微放慢速度以取得更好的結果。因此新病患進來時,我們會讓他們在 Quick Start 計畫中停留久一點,確保我們能為保險公司準備非常完整的個案資料,從而提升付費用藥的比例。我們也看到這樣做正在奏效。在我們的商業保險族群(約占病患的 60%)中,目前超過 80% 已經是付費治療。這些趨勢讓我們對長期達到 85% 更有信心。

  • As far as where we're going to end the end of the year, I don't even want to make a prediction. I think it's -- this is all about that longer-term progress. And as Jon noted, we don't expect a meaningful change in 2024, but the percentage changes will start to improve in 2025, '26 and '27, that's when we'll start to notice it.

    至於年底會落在哪裡,我甚至不想做預測。我認為——這一切都關乎更長期的進展。如 Jon 所說,我們不預期 2024 年會有顯著變化,但比例的改善會在 2025、2026 和 2027 年開始更明顯,那時我們才會真正注意到。

  • Unidentified Analyst

    Unidentified Analyst

  • Got it. That makes sense. I guess a quick follow-up on the third quarter sales. We -- are you now seeing more patients coming from prophy naive patients or converted patients in the U.S. And should we assume maybe more of a revenue growth ex U.S. are from prophy naive patients?

    了解,這很合理。我想快速追問一下第三季的銷售。我們——你們現在在美國看到更多病患是來自先前使用預防治療(prophy)的轉換者,還是來自未曾使用預防治療(prophy naive)的病患?另外,我們是否可以假設美國以外的營收成長更多是來自 prophy naive 病患?

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • So in the U.S., the trends are really the same. It's that roughly 50-50 split between patients coming over from prophy or prophy naive at least most recently that they're not on prophy. That has been -- it's not exactly the same every quarter like anything else, but it's been really consistent over time. Ex-U.S. yes, we get a lot more patients who are prophy naive because the prophy market in general has trailed the U.S. ex U.S., but that's starting to change. And so we get some switches from other prophy ex U.S., but most of it is people coming on to prophy for the first time now that they can do it with a targeted oral therapy.

    在美國,趨勢其實差不多。大約是 50/50 的分布:一半是從既有預防治療轉過來的病患,另一半是 prophy naive,或至少最近並未在使用預防治療的病患。這——就像其他事情一樣,每一季不會完全一模一樣,但長期來看一直相當一致。美國以外市場方面,是的,我們有更多 prophy naive 病患,因為整體而言,美國以外的預防治療市場落後於美國,但這正在開始改變。因此我們也會看到一些從其他預防治療轉換過來的病患,但大多數仍是第一次開始使用預防治療的人,因為現在他們可以用一個標靶的口服療法來做到。

  • Operator

    Operator

  • The next question is from Brian Abrahams of RBC Capital Markets.

    下一個問題來自 RBC Capital Markets 的 Brian Abrahams。

  • Unidentified Analyst

    Unidentified Analyst

  • Everyone, this is [Nevin] on for Brian. Congrats on the quarter. And we really appreciate some of the color that you gave around some of the sales trajectory that you expect for the coming years. On that, I just wanted to ask in Slide 4, some of the data that you had regarding net patient growth and also some of the discontinuations. It seems that perhaps some of the discontinuations are leveling off or perhaps maybe changing dynamics. Could you maybe speak to whether you are seeing improvements in the retention rate and whether that's affected by your kind of push to better educate patients? And then I have a quick follow-up as well.

    各位好,我是 [Nevin] 代替 Brian 發問。恭喜本季表現。我們也非常感謝你們分享了對未來幾年銷售走勢的一些看法。針對這點,我想問一下投影片 4 中你們提供的淨病患成長以及停用(discontinuations)的一些數據。看起來停用可能正在趨於平穩,或是動態有所改變。你能否談談你們是否看到留存率(retention rate)有所改善?以及這是否與你們推動更好地教育病患有關?我也有一個簡短的追問。

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • Sure. No. So good analysis of the data. Yes, I think we have seen it improve certainly from what we experienced very early in the launch and it is exactly that. It's setting expectations. We do that all the way through everything that we can do with health care providers to make sure they talk to their patients, when our patient services teams talk to patients they set expectations. And we think that, that has really paid off. The market is getting very familiar now with ORLADEYO. Physicians and other health care providers know the drug. They have confidence in it. Patients now know a lot more and they have confidence in it. And in a condition like HAE, where stress can cause attacks, having confidence in your therapy is important. So we think that's all part of the pattern settling out, and we're very confident in this pattern going forward.

    當然。你的數據解讀很好。是的,我認為相較於上市初期我們非常早期的經驗,確實已經改善,而原因正是你說的:設定預期。我們透過所有能做的事情來達成——與醫療照護提供者合作,確保他們與病患溝通;當我們的病患服務團隊與病患對話時,也會設定預期。我們認為這確實帶來了成效。市場現在對 ORLADEYO 已經非常熟悉。醫師與其他醫療照護提供者了解這個藥,並對它有信心。病患現在也知道得更多,對它也更有信心。在像 HAE 這種壓力可能引發發作的疾病中,對治療有信心很重要。因此我們認為這都是整體模式逐漸穩定的一部分,我們對未來延續這個模式非常有信心。

  • Unidentified Analyst

    Unidentified Analyst

  • So and kind of like a follow-up to that, can you also speak a little bit to the trial progress for ORLADEYO in pediatric patients with the sprinkle formulation? And is there perhaps anything you could tell us about what those retention metrics might look like within the pediatric patients so far? And if any differences in the GI tox that you might be seeing in this population?

    那麼作為追問,你也能談談 ORLADEYO 在兒科病患、使用撒粉劑型(sprinkle formulation)的試驗進度嗎?另外,到目前為止,你們在兒科病患中的留存指標大概是什麼樣子?以及在這個族群中是否看到任何腸胃道毒性(GI tox)的差異?

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • So the trial enrollment is going well. I'll defer other questions to tomorrow. In our R&D Day, we will be addressing that amongst our other programs. But what I'll say is the trial is going well, and there's a huge need. There's a need for an oral therapy across the market, as you can imagine, in pediatrics, no parent or caregiver likes to inject their child and no child likes to be injected. And with HAE, fortunately, a lot of the kids don't become symptomatic until puberty, but about 4 in 10 patients actually have their first attack by age 5. And so there's a huge need to have an oral therapy that can prevent attacks so that these kids can live a normal life. And that's what we're shooting for. And we think we're optimistic we're going to have a great product to do that.

    試驗收案進展良好。其他問題我先留到明天再談;在我們的研發日(R&D Day)上,會連同其他專案一起說明。不過我可以說的是,試驗進行得很順利,而且需求非常大。你可以想像,在兒科市場對口服療法的需求很高,沒有任何父母或照護者喜歡替孩子打針,也沒有孩子喜歡被打針。就 HAE 而言,幸運的是很多孩子要到青春期才會出現症狀,但大約每 10 位病患中就有 4 位在 5 歲前就會首次發作。因此非常需要一種能預防發作的口服療法,讓這些孩子能過正常生活。這就是我們努力的方向。我們也樂觀地認為,我們將會有一個很好的產品來做到這點。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Nevin, a really good indicator of you've got something of real need for patients is when your enrollment goes really well and enrollment is going really well in this trial.

    Nevin,一個很好的指標可以顯示你做的是病患真正需要的東西,就是當你的收案進展非常順利;而這項試驗的收案確實進展得非常順利。

  • Operator

    Operator

  • The next question is from Jon Wolleben of JMP.

    下一個問題來自 JMP 的 Jon Wolleben。

  • Unidentified Analyst

    Unidentified Analyst

  • This is Catherine on for Jon. I just have a quick question about kind of just what's been working well in the ex U.S. launch of ORLADEYO, I know you kind of hit upon the thought that you're gaining ground with reimbursement dynamics. But any other color you could provide?

    我是 Catherine 代替 Jon 發問。我想快速問一下,ORLADEYO 在美國以外市場的上市推進方面,哪些做法特別奏效?我知道你剛提到你們在給付(reimbursement)動態上正在取得進展,但還有沒有其他可以補充的細節?

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • I think, sure, a couple of things. I'll touch on the reimbursement first because that ex U.S. anywhere getting access to products, having someone pay for it is really critical for patients to be able to get their therapy. So an example that I've cited before in the United Kingdom, where ORLADEYO is covered, NICE approved ORLADEYO for patients with 2 attacks, HAE attacks or more per month. Whereas other modern prophy therapies like TAKHZYRO were limited to patients with 2 attacks a week or more, which is a very small segment of the market. And so our team has been able to take advantage of that and really help a lot of patients with ORLADEYO.

    我想可以,幾點。我先談給付,因為在美國以外的任何地方,要讓產品取得可近性、有人願意付費,對病患能否拿到治療非常關鍵。我之前舉過一個例子:在英國,ORLADEYO 已納入給付,NICE 核准 ORLADEYO 用於每月有 2 次或以上 HAE 發作的病患;而其他現代預防治療(prophy)如 TAKHZYRO,則限制在每週 2 次或以上發作的病患,這只涵蓋市場中非常小的一部分。因此我們的團隊得以善用這一點,並用 ORLADEYO 真正幫助到很多病患。

  • And then I think the other factor is just what I mentioned on one of the earlier questions, which is until a few years ago, there were -- there was very little availability of modern prophylaxis outside of the U.S. And so the patient community, the physician communities in these different markets were just not used to using prophylaxis. All they had were androgen steroids or some other very nonspecific drugs. Now they have access to those drugs. And so it's changing how they view treatment and everyone is aligning around the global guidelines, which says that one of the modern prophylaxis therapy should be considered for all product -- all patients and that's what we see happening.

    另外一個因素是我在前面某個問題也提到的:直到幾年前,美國以外市場——現代預防治療的可得性非常有限。因此在這些不同市場中,病患社群與醫師社群並不習慣使用預防治療;他們只有雄性激素類固醇或其他非常不具特異性的藥物。現在他們能取得這些現代藥物了,因此正在改變他們對治療的看法,而大家也逐步與全球指引一致:指引指出,所有病患都應考慮使用一種現代預防治療——這正是我們看到正在發生的事情。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • I think one other thing is like the U.S., Charlie and the GM, Abid Karim and Europe have done a great job of building a really good team, really experienced team that hits the ground running and while data access and there's some challenges in Europe. They work closely with Jinky's team, and they're -- just like in the U.S., when they see a challenge, they adapt and adjust and it's been really impressive to watch the European team.

    我認為另外一點是,像在美國一樣,Charlie 和總經理(GM)、Abid Karim 以及歐洲團隊在建立一支非常優秀、經驗豐富、能夠迅速上手的團隊方面做得非常出色;雖然在歐洲取得資料存取仍有一些挑戰。他們與 Jinky 的團隊密切合作,而且——就像在美國一樣——當他們看到挑戰時,就會調整與因應,觀察歐洲團隊的表現真的令人印象深刻。

  • Unidentified Analyst

    Unidentified Analyst

  • And then I just have one more question about the pediatric opportunity. I know that you're going to kind of save the developmental pipeline for tomorrow, but just a comment on that.

    然後我還有一個關於兒科機會的問題。我知道你們會把研發管線留到明天再談,但想請你們就此做個簡短評論。

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • Sure. Just to add a small piece to what I said earlier. The pediatric market in the U.S., I think we've said this before, we think there in the neighborhood of 500 patients who are probably with HAE and symptomatic. And not all of those will need prophylaxis right away. But the real key with where HAE therapy has evolved is that now there are options, what the experts -- they really see patients growing up without -- in a very different environment than even 10 years ago.

    當然。我想在我先前所說的基礎上再補充一小點。美國的兒科市場,我想我們以前也說過,我們認為大約有 500 名左右的病患可能患有 HAE 且有症狀。並不是所有人都會立刻需要預防性治療。但 HAE 治療演進的關鍵在於,現在已有不同選項;專家們——他們確實看到病患在成長過程中所處的環境,與甚至 10 年前相比已非常不同。

  • So kids today can grow up, they can get control of their attacks. They can do all normal school activities, everything else. But the goal is to be completely normal. And that just hasn't happened with previous generation. So just the availability of prophylaxis for pediatric population. And we hope soon an oral prophy product is what's really going to change the lives of these kids and these families, frankly.

    所以現在的孩子可以在成長過程中控制發作,可以參與所有正常的學校活動以及其他一切。但目標是能夠完全正常。而這在上一代治療中並未真正實現。因此,兒科族群能夠使用預防性治療的可近性非常重要。我們也希望不久後能有口服預防產品,這才是真正會改變這些孩子與這些家庭生活的關鍵,坦白說。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Yes, I can remember, and this isn't that long ago, 10 years ago, when you would talked to young women that had HAE and they weren't even sure if they wanted to have children and now you can live with HAE at a very young age and manage your HAE. So we're so excited about this formulation. [Bill Sharon] and I have chased that patient meetings for a decade from mothers that are saying go faster, and it's really exciting that we're on the cusp of getting there.

    是的,我還記得——而且其實也沒有很久以前——10 年前,當你和患有 HAE 的年輕女性交談時,她們甚至不確定自己是否想要生小孩;而現在,你可以在很年輕的時候就與 HAE 共存並管理 HAE。我們對這個劑型非常興奮。[Bill Sharon] 和我追著參加那種病友會已經十年了,許多母親都在說「再快一點」,而我們正站在即將達成的門檻上,真的令人振奮。

  • Operator

    Operator

  • The next question is from Liisa Bayko with Evercore ISI.

    下一個問題來自 Evercore ISI 的 Liisa Bayko。

  • Liisa Ann Bayko - MD & Fundamental Research Analyst

    Liisa Ann Bayko - MD & Fundamental Research Analyst

  • Sorry about that. I just want to follow up on an earlier question regarding the linear growth of 200 patients per year. What kind of underlies your confidence that you can continue growing at that rate? How many patients would have cycled through by I guess, '29. Would all patients have touched ORLADEYO at some point? Are there benchmarks you can point to? Is that pretty typical to see discontinued new patient adds at a consistent level from like launch. It seems like at the early launch period, you might have a different trajectory. So that's why I was just curious about the kind of 200 patients being added per year.

    抱歉。我要追問先前一個關於每年線性成長 200 名病患的問題。你們有什麼依據讓你們有信心可以持續以這個速度成長?到我想是 2029 年為止,會有多少病患輪替過?是否所有病患在某個時間點都會接觸到 ORLADEYO?你們能指出哪些基準嗎?從上市開始就能在穩定水準下持續新增病患、同時也有停用的情況,這算是典型現象嗎?看起來在早期上市階段,軌跡可能會不同,所以我才好奇為什麼是每年新增 200 名病患。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Charlie is going to answer the first part, but I want Jinky to dive in as well because she's got insight into the future as well to the data she has gathered.

    Charlie 會回答第一部分,但我也想請 Jinky 一起深入說明,因為她對未來以及她蒐集到的資料也有洞見。

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • Yes. And Liisa, we realized that the ORLADEYO launch is not like your classic rare disease launch of the past. And I think it's a point Jon made earlier, this is -- and Jinky was making in her comments, it's a crowded market. And I may steal some of Jinky's thunder, but she said it, but these patients are sticky. And so it's this is a slower moving but consistently moving launch. And then I think, Jinky, maybe can you comment on again, reiterate how we use the data. It really comes down to the insights and the data that we get from Jinky and her team.

    是的。Liisa,我們也意識到 ORLADEYO 的上市推進並不像過去典型的罕見疾病產品上市。我想 Jon 先前也提到過這點——而 Jinky 在她的評論中也提到——這是一個競爭擁擠的市場。我可能會搶走 Jinky 的一些重點,但她確實說過:這些病患黏著度很高。所以這是一個移動較慢、但持續推進的上市曲線。然後我想,Jinky,你也許可以再評論一下、重申我們如何使用資料。歸根結底,這取決於我們從 Jinky 和她的團隊獲得的洞察與數據。

  • Unidentified Company Representative

    Unidentified Company Representative

  • Yes. I mean we triangulate, right, because it's imperfect in every way in terms of the rare disease market and data availability. So we take the market insights and the research that we do all the methods that I described in the remarks, and basically model that out. And so our physicians and our patients are telling us the demand is -- they're still saying that they want more. And so the minute that changes, that landscape changes, we're all going to know about it because we consistently follow it every quarter. I say that demand and the numbers that Charlie are using in this model are our numbers, right? So essentially, we're triangulating based on what the market is telling us and then marrying it with the actual ORLADEYO and that ramp within our sort of database of ORLADEYO patients to give us that confidence.

    是的。我們會做三角驗證(triangulate),對吧?因為在罕見疾病市場與資料可得性方面,各方面都不完美。所以我們會把市場洞察與我們做的研究——也就是我在發言中描述的所有方法——整合起來,基本上建立模型。因此,我們的醫師與病患告訴我們需求——他們仍在說他們想要更多。所以一旦這點改變、整個環境改變,我們都會知道,因為我們每一季都持續追蹤。我想說的是,Charlie 在這個模型中使用的需求與數字就是我們的數字,對吧?所以本質上,我們是根據市場告訴我們的訊息做三角驗證,並把它與 ORLADEYO 的實際情況,以及在我們 ORLADEYO 病患資料庫中看到的爬坡(ramp)結合,來建立這份信心。

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • I'll come back to one other point, which is to address your question, Liisa, about are we -- are all patients going to cycle through. That ultimately is our goal. But if every patient cycles through ORLADEYO, we'll come back and talk to you about how this has changed. It's more than $1 billion. We don't need every patient to go through to get to $1 billion. On a monthly basis, any given month, 5% to 10% of the patients with new start forms are actually patients who dropped off at some point in the past and are coming back, so there is that component. But if we reach 4,000, 5,000 patients in the U.S., we will easily get to 2,000 steady state sticky patients by 2029.

    我再回到另一個點,來回應你的問題,Liisa,也就是我們是否——是否所有病患都會輪替使用。那最終確實是我們的目標。但如果每位病患都輪替使用 ORLADEYO,我們會再回來跟你討論這對業績的改變。那會超過 10 億美元。我們不需要每位病患都使用,才能達到 10 億美元。以每個月來看,任何一個月份,新啟用表單(new start forms)中有 5% 到 10% 的病患,其實是過去某個時間點曾停用、現在又回來的病患,所以也有這個組成。但如果我們在美國達到 4,000、5,000 名病患,到 2029 年我們很容易就能達到 2,000 名穩態、黏著度高的病患。

  • Liisa Ann Bayko - MD & Fundamental Research Analyst

    Liisa Ann Bayko - MD & Fundamental Research Analyst

  • Okay. Great. And then just a question on the pediatric, how many pediatrics would be eligible per your calculation?

    好的。很好。然後再問一個關於兒科的問題,依你們的計算,有多少兒科病患會符合用藥資格?

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • So we think the number in the U.S. market, the number of kids could be in the 500 patient range who could be eligible for prophylaxis. That doesn't mean 500 will be on ORLADEYO or any other prophy. But the pediatric side of the market is one that is still going to evolve because it's only been in the last few years that prophy has even been available. It's all injectable right now. And so we think that our views on that could change, but we think 500 patients is a pretty decent estimate right now.

    所以我們認為在美國市場,符合預防性治療資格的兒童人數可能在 500 名左右。這不代表 500 名都會使用 ORLADEYO 或任何其他預防性治療。但兒科市場仍會持續演變,因為直到最近幾年預防性治療才真正可用;目前全都是注射劑型。因此我們認為我們對這部分的看法可能會改變,但就目前而言,500 名病患是一個相當不錯的估計。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • And Liisa, one other thing I'd add, it's hard to quantify, but I think we've seen this with the adolescent population is this halo effect that happens in families. Remember, it's a hereditary disease and what see is when adolescents have done really well in a family, all of a sudden, the mother or the father who has HAE is like, well, maybe I should try that. And I think the same thing is going to happen with pediatric patients.

    Liisa,我還想補充一點:這很難量化,但我認為我們在青少年族群已經看到一種「光環效應」(halo effect)會在家庭中發生。記得這是遺傳性疾病,而我們看到的是,當家中的青少年使用後效果很好時,突然之間,患有 HAE 的母親或父親就會想:那也許我也該試試看。我認為同樣的事情也會在兒科病患上發生。

  • Liisa Ann Bayko - MD & Fundamental Research Analyst

    Liisa Ann Bayko - MD & Fundamental Research Analyst

  • Okay. And then just a quick question just on the expense side. It looks like you're kind of higher towards the end of this year in the fourth quarter per your guidance. Is that how we should sort of think about the run rate going forward into next year? Maybe you could just provide some color on the kind of the expense trajectory into the fourth from the...

    好的。然後再快速問一個費用端的問題。依你們的指引,看起來今年年底第四季的費用會比較高。那我們是否應該把這視為明年延續的費用運行率(run rate)?也許你們可以提供一些關於費用走勢、從……到第四季的說明。

  • Anthony J. Doyle - Senior VP & CFO

    Anthony J. Doyle - Senior VP & CFO

  • Yes. We've given a revised range based on what we see. And so based on where we are and what we will share with everybody tomorrow at the R&D Day, we'll give some additional flavor specifically around R&D expenditure. But I think we're well positioned to see growth in revenue. I think we will see some additional growth in that OpEx line. But we are always going to be very careful, very thoughtful around capital expenditure and making sure that the things that we invest in I think that we think will create value. We will give some more additional details more.

    是的。我們已根據我們所看到的情況給出修訂後的區間。因此,基於我們目前的位置,以及我們明天在研發日(R&D Day)會與大家分享的內容,我們會提供更多細節,特別是關於研發支出(R&D expenditure)。但我認為我們在推動營收成長方面處於很好的位置。我想我們也會在營運費用(OpEx)那一行看到一些額外成長。但我們在資本支出(capital expenditure)方面一向會非常謹慎、非常周全,確保我們投資的項目是我們認為能創造價值的。我們之後會再提供更多細節。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • I would add to that, that when you combine growing revenue with discipline around capital allocation, you're getting a lot closer to a situation where your cash needs to the company are self-sufficient, right? And we're getting there. Tomorrow, really excited about what we're going to share with you. But another really important piece is having clear go-no decisions and being disciplined about the bar we've set and when we continue to invest or when we stop. And we've got a track record of that and we'll continue that.

    我再補充一點:當你把營收成長與資本配置的紀律結合起來,你就更接近一種狀態——公司的現金需求可以自給自足,對吧?而我們正在達成那個目標。明天我們非常期待能與你分享我們要說的內容。但另一個非常重要的部分,是要有清楚的 go-no 決策,並且對我們設定的門檻保持紀律,決定何時繼續投資、何時停止。我們在這方面有過往紀錄,也會持續如此。

  • Operator

    Operator

  • The next question is from Serge Belanger of Needham and Company.

    下一個問題來自 Needham and Company 的 Serge Belanger。

  • Serge D. Belanger - Senior Analyst

    Serge D. Belanger - Senior Analyst

  • Appreciate the additional detail on ORLADEYO trends. I guess 2 for Charlie. We saw the percentage of patients on free product creep up late in the year last year. Just curious what you're seeing on that front. And then I think earlier this year, there was an issue with the lack of funding for co-payment support programs that led you to start the year on I guess, with a higher base of patients on free product as we get closer to 2024, is that an issue that could replicate itself?

    感謝你們提供 ORLADEYO 趨勢的更多細節。我想有兩個問題給 Charlie。去年年底我們看到使用免費產品(free product)的病患比例略有上升。想請問你們目前在這方面看到什麼情況?另外,我記得今年稍早曾有共同支付(co-payment)補助計畫資金不足的問題,導致你們在年初時——我想——以較高的免費產品病患基數開始。隨著接近 2024 年,這是否可能再次發生?

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • Sure. Thanks, Serge. So first on the percentage creeping up at the end of last year. I think as I made a couple of comments on an earlier question, its reauthorization -- not -- sorry, re-enrollment season right now and so there are some patients who are switching around plans. Things did creep up a little in Q4. I don't know what will happen -- or Q3. I don't know what will happen in Q4, but it's not likely to get better. I'd point you to what I said earlier, which is this is a long multiyear game in terms of how we see this improvement in paid happening. But it's probably not going to get better in Q4, but we have confidence in the long term.

    當然。謝謝你,Serge。首先談到去年年底比例略有上升。我想正如我在先前一個問題中提到的幾點,現在是重新授權——不是——抱歉,是重新投保季,所以有些病患正在不同方案之間轉換。第四季確實略有上升。我不知道——或第三季。我不知道第四季會發生什麼,但不太可能變好。我會請你參考我先前說過的:就我們如何看待「付費」改善的發生而言,這是一場長期、跨多年的戰役。但第四季可能不會變好,不過我們對長期仍有信心。

  • As far as the co-payment assistance in the Medicare from earlier this year. That issue is still going on. It's been going on all year. We don't know what's going to happen next year. Also, the IRA starts to kick in next year. So that's going to lead to some different dynamics. And so I would assume kind of similar dynamics, but we don't know at this point. We'll just have to wait and see how the early part of next year plays out outside of our control.

    至於今年稍早提到的 Medicare 共付額補助,那個問題仍在持續。它整年都在發生。我們不知道明年會怎麼樣。另外,IRA 明年開始逐步生效,所以會帶來一些不同的動態。因此我會假設大致會是類似的動態,但目前我們還不確定。我們只能等待觀察明年年初在我們控制範圍之外的情況如何發展。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Yes. I think the realistic way of looking at it is we're going to plan for a conservative case of there's going to be headwinds next year. So that's why we're saying don't expect a lot of progress on free to pay next year.

    是的。我認為比較務實的看法是,我們會以保守情境來規劃:明年會有逆風。所以我們才會說,明年不要期待在「免費轉付費」方面有太多進展。

  • Serge D. Belanger - Senior Analyst

    Serge D. Belanger - Senior Analyst

  • Okay. And then on your path to $800 million in U.S. revenues in 2029, what assumptions do you make for the competitive landscape during that time frame?

    好的。那麼關於你們在 2029 年達到美國營收 8 億美元的路徑,在那段期間你們對競爭格局做了哪些假設?

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • I think let's have Jinky answer this one because I think she's got the best insight into this and some of the comments you made are really important to reinforce.

    我想讓 Jinky 來回答這題,因為我認為她對此最有洞見,而且你剛才的一些評論也非常重要,值得再強調。

  • Jinky Ang Rosselli - Chief Data & Insights Officer

    Jinky Ang Rosselli - Chief Data & Insights Officer

  • Yes. So we talk about the modeling, right, and sort of how we do the research, the quantitative work with our base of patients and physicians. We share the profile of the competitive landscape, right? So for each competitor coming into the space, we present them with the opportunity to allocate patients to those competitors. And so what Charlie is using as sort of assumptions are all built out of those simulations, right, or the preference shares which then kind of pushed into the simulator. And the simulator then gives you a sense for where ORLADEYO is going to land within the contact with the competitors. So all the competitive -- like all the competitive dynamics are built into the assumptions.

    是的。所以我們談到建模,對吧,以及我們如何做研究——也就是針對我們的病患與醫師基礎所做的量化研究工作。我們會分享競爭格局的輪廓,對吧?因此對於每一個進入這個領域的競爭者,我們會提供受訪者一個機會,把病患分配給那些競爭者。Charlie 所使用的各項假設,都是從那些模擬中建立出來的,對吧?或是偏好占比,然後再把它們輸入到模擬器裡。模擬器接著會讓你了解 ORLADEYO 在與競爭者接觸的情境下會落在什麼位置。因此所有競爭——也就是所有競爭動態都已經內建在這些假設之中。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Yes. So just a couple of other things to stress that you might not have caught. She is assuming everybody succeeds, right, which is probably not going to happen, but we're being really conservative and we're seeing everybody gets to the market. And the other thing that she emphasized was injectables are going to take from injectables, right? And orals aren't going to take from ORLADEYO because there's not an incremental benefit if you're controlled on a once a day therapy.

    是的。再強調幾點你可能沒注意到的。她的假設是每個人都會成功,對吧?這大概不會發生,但我們採取非常保守的做法,假設每個人都能進入市場。另一點她強調的是:注射劑會從注射劑那邊搶份額,對吧?而口服藥不會從 ORLADEYO 那邊搶,因為如果你已經在每日一次的療法下控制良好,就沒有額外的增量效益。

  • Jinky Ang Rosselli - Chief Data & Insights Officer

    Jinky Ang Rosselli - Chief Data & Insights Officer

  • Yes, it's not meaningful enough. It's not worth to switch for them.

    是的,差異不夠顯著,不值得他們為此轉換。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • So while we're factoring it in, the impact to ORLADEYO is minimal.

    所以即使我們把它納入考量,對 ORLADEYO 的影響也很小。

  • Jinky Ang Rosselli - Chief Data & Insights Officer

    Jinky Ang Rosselli - Chief Data & Insights Officer

  • That's right.

    沒錯。

  • Operator

    Operator

  • The next question is from Gena Wang with Barclays.

    下一個問題來自 Barclays 的 Gena Wang。

  • Harshita Polishetty - Analyst

    Harshita Polishetty - Analyst

  • This is Harshita on for Gena. I had a couple of quick ones on ORLADEYO. And then one on Factor D, I guess I'll ask the factor D one first. Are you going to give an update tomorrow if so I'll defer the questions tomorrow on Factor D. If not, I was wondering if you could give a quick update on that program today.

    我是代替 Gena 的 Harshita。我有幾個關於 ORLADEYO 的快速問題,另外還有一個關於 Factor D 的問題。我想我先問 Factor D:你們明天會更新嗎?如果會,我就把 Factor D 的問題留到明天。如果不會,我想請你們今天能否簡要更新一下那個計畫。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Save it for tomorrow.

    留到明天。

  • Harshita Polishetty - Analyst

    Harshita Polishetty - Analyst

  • Okay. Perfect. So on ORLADEYO, I think one metric you haven't talked about yet was the new prescription starts. How do you see the -- how was it in this quarter versus in the future? Is it still -- do you still expect 50% of new prescriptions from Tier 1? I just wanted some color on that.

    好的。太好了。那關於 ORLADEYO,我想有一個你們還沒談到的指標是新處方啟動(new prescription starts)。你們怎麼看——本季相較於未來的情況如何?你們是否仍預期 50% 的新處方來自 Tier 1?我想了解一些背景。

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • Yes. No, you're right. I did not talk about the physician source. It's really consistent with what it's always been. So we're getting about half from the Tier 1 that covers about half the market and half from everyone else. And our team has done a fantastic job of really reaching far doing a great job of moving the big prescribers and some of that, it's hard work that is gradual progress, as Jon, Jinky and I have been describing, but then also seeking out patients in even a practice that might have one patient, they are there. And for a small team, they've covered a lot of ground and do it really efficiently.

    是的。不,你說得對。我確實沒有談到醫師來源。它其實和以往一直都很一致。我們大約有一半來自 Tier 1(涵蓋約一半市場),另一半來自其他所有人。我們的團隊做得非常出色,觸及範圍很廣,在推動大型開立者方面做得很好;其中一部分是艱辛的工作、逐步的進展,正如 Jon、Jinky 和我一直在描述的那樣;同時也會在某些可能只有一位病患的診所中尋找病患,他們也會去。以一個小團隊來說,他們覆蓋了非常多的區域,而且效率很高。

  • Harshita Polishetty - Analyst

    Harshita Polishetty - Analyst

  • Perfect. That's really helpful. And the next quick clarification question is, in Jinky's prepared remarks, I think you mentioned a comment on 25% of HAE prescribers are going to prescribe ORLADEYO. I can't remember what was the comment. I just wanted a quick clarification on that. And what was the sample size of the HAE docs?

    很好,這很有幫助。下一個快速釐清問題是:在 Jinky 的事先準備發言中,我記得你提到一個關於 25% 的 HAE 開立者將會開立 ORLADEYO 的評論。我不太記得那句話的內容,想請你快速釐清一下。另外 HAE 醫師的樣本數是多少?

  • Jinky Ang Rosselli - Chief Data & Insights Officer

    Jinky Ang Rosselli - Chief Data & Insights Officer

  • Yes. So that's the quarterly measure of demand that we use. So we ask sort of what they're currently prescribing and then we ask future prescribing in the next 12 months, and that's the 25%. And that's been consistent way -- sorry, study over study and that level of demand. So they are anticipating growth in their prescribing over the next 12 months.

    是的。那是我們使用的每季需求衡量指標。所以我們會問他們目前在開立什麼,然後也會問未來 12 個月的開立情況,而那就是 25%。而且那一直都很一致——抱歉,是一個研究接著一個研究都一致,顯示那個需求水準。所以他們預期在未來 12 個月內,他們的開立量會成長。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Yes. Let me just put a fine point on that. That's 25% of their patients they'll prescribe ORLADEYO. Not 25% of the docs and then the sample size, Jinky.

    是的。我再把重點講清楚一點:那是指他們的病患中有 25% 會開立 ORLADEYO,不是指 25% 的醫師。至於樣本數,Jinky?

  • Jinky Ang Rosselli - Chief Data & Insights Officer

    Jinky Ang Rosselli - Chief Data & Insights Officer

  • Yes. The sample size for the quarterly pulses are 65 allergy and immunologists, in our larger studies, which we do once a year, they're what I said 175 [ACPs].

    是的。每季脈動調查(quarterly pulses)的樣本數是 65 位過敏與免疫科醫師;在我們一年做一次的較大型研究中,樣本數是我提到的 175 位 [ACPs]。

  • Operator

    Operator

  • The next question is from Jacqueline Lu of Oppenheimer.

    下一個問題來自 Oppenheimer 的 Jacqueline Lu。

  • Jacqueline Lu - Research Analyst

    Jacqueline Lu - Research Analyst

  • This is Jacqueline on Justin's team. Could you provide a little bit more insights for tomorrow. So you guys specifically, could you comment on the complement therapeutics and the landscape. Where the unmet need exists for 10013 and particularly data insight and (inaudible) factor D inhibitors.

    我是 Justin 團隊的 Jacqueline。想請你們為明天提供更多洞見。你們能否特別評論補體治療(complement therapeutics)及其競爭格局?10013 的未滿足需求在哪裡,尤其是數據洞見以及(聽不清)Factor D 抑制劑。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Yes. I'm not going to get into the details today. All I'm going to tell you is don't miss it. This is going to be different from other R&D days that you participated in, and you're going to get insight into our pipeline and how we discover drugs that I think is we're paying attention to.

    是的。我今天不會深入細節。我唯一要告訴你的是:不要錯過。這會和你們參加過的其他研發日不同,你們將會更深入了解我們的產品線,以及我們如何發現藥物——我認為這是值得關注的。

  • Charles K. Gayer - Senior VP & Chief Commercial Officer

    Charles K. Gayer - Senior VP & Chief Commercial Officer

  • You will get a lot more than 10013.

    你們會得到的不只 10013。

  • Operator

    Operator

  • This concludes our question-and-answer session. I would like to turn the conference back over to Jon Stonehouse for any closing remarks.

    我們的問答環節到此結束。我想把電話會議交回給 Jon Stonehouse,請他做結語。

  • Jon P. Stonehouse - CEO, President & Executive Director

    Jon P. Stonehouse - CEO, President & Executive Director

  • Yes. Thank you. So today, it was all about ORLADEYO and our goal to give you better insight into what we see both today in the marketplace and the trends that we see in the growth and then also how we see the market shaping up in the future. So hopefully, you found that very helpful. Tomorrow is all about the pipeline. And as Charlie said, it's about how we're expanding the pipeline and also how we're discovering first-in-class and best-in-class molecules, and then how we'll be very careful and have clear go, no-go decisions around capital allocation. So please tune in. We're really looking forward. We appreciate those of you that are making the trek here to Birmingham, Alabama, and look forward to talking to you tomorrow.

    是的,謝謝。今天的重點完全是 ORLADEYO,我們的目標是讓各位更深入了解:我們今天在市場上看到的情況、我們在成長中看到的趨勢,以及我們如何看待未來市場的走向。所以希望你們覺得很有幫助。明天的重點完全是產品線(pipeline)。正如 Charlie 所說,內容包括我們如何擴展產品線、如何發現同類首創(first-in-class)與同類最佳(best-in-class)的分子,以及我們將如何非常謹慎地、以明確的 go/no-go 決策來進行資本配置。所以請務必收看。我們非常期待。也感謝各位遠道而來到阿拉巴馬州伯明翰,我們期待明天與各位交流。

  • Operator

    Operator

  • The conference is now concluded. Thank you for attending today's presentation. You may now disconnect. Thank you.

    本次會議到此結束。感謝各位參加今天的簡報。您現在可以中斷連線。謝謝。